UNSPSC 51283606: Rifamycin amp

This classification denotes an antitubercular agent with the molecular formula C43H58N4O12, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier VJT6J7R4TR, chemically known as rifamycin, 3-(((4-methyl-1-piperazinyl)imino)methyl)-, but more generally known as rifamycin amp, which bears US NIH Compound Identifier 5381226. European Medicines Agency schedules rifamycin amp or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10310MIG.

Most nations, for tariff purposes, schedule rifamycin amp under HS 29419000. SMILES: CC1C(C2C3C4C1O[C@@](C4=O)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]([C@H](/C=C/C=C(\C(=O)NC(C2O)C(C3O)C=NN5CCN(CC5)C)/C)C)O)C)O)C)OC(=O)C)C)OC)C)O.

UNSPSC 51283606 Rifamycin amp is a Commodity code for injectable rifamycin products, but the recent state and local opportunities tagged under this code show little activity directly aligned with rifamycin procurement. The Illinois Department of Public Health's piggyback pharmaceutical warehouse contract awarded to Chartwell Rx LLC in August 2026 supplies oral antibiotics (Doxycycline Hyclate and Ciprofloxacin Hydrochloride), not rifamycin injections. The Seminole County, Florida procurement focuses on naloxone and drug deactivation systems for community health initiatives. State and local health departments and county health agencies appear to be the primary issuing bodies using this taxonomy family for pharmaceutical procurement, though the recent records show demand clustering around emergency response medications and broad-spectrum oral antibiotics rather than rifamycin ampules specifically.

The code shows activity in Illinois and Florida based on the most recent opportunities, though the volume and specificity of rifamycin-focused solicitations remain unclear from the available records. The Illinois Department of Public Health's $2,999,999.11 three-year piggyback contract through the MMCAP Infuse consortium (awarded August 28, 2026) demonstrates state-level pharmaceutical procurement through cooperative purchasing vehicles with quarterly or recurring delivery models. Seminole County's IFB for naloxone and drug deactivation systems (posted June 30, 2026, response deadline July 26, 2026) indicates county-level health procurement with fixed-fee bidding and multi-year terms. The mismatch between the code's nominal scope and the actual solicitations tagged under it suggests that state and local procurement offices may use rifamycin ampule codes inconsistently or that recent demand lies elsewhere in the pharmaceutical taxonomy. Vendors pursuing this code should verify recent RFP and ITB activity directly with state health departments and county health authorities rather than relying on code-level posting volume.